Filtered By:
Source: Amgen News Release
Education: Study
Procedure: Ultrasound
Countries: Spain Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Amgen To Present New Data From The Repatha ® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017
Analysis Evaluates the Effect of Repatha in More Than 5,000 Patients With a History of Stroke THOUSAND OAKS, Calif., Aug. 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the Repatha® (evolocumab) clinical trial program, including three late-breaking scientific sessions, will be presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain, Aug. 26-30, 2017. New data includes additional efficacy and safety analyses from the Repatha cardiovascular outcomes trial (FOURIER) and the Repatha coronary intravascular ultrasound imaging trial (GLAGOV). "Data from t...
Source: Amgen News Release - August 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news